Proficio Capital Partners LLC Acquires Shares of 19,952 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Proficio Capital Partners LLC bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 4th quarter, Holdings Channel.com reports. The firm bought 19,952 shares of the company’s stock, valued at approximately $376,000.

Other hedge funds also recently made changes to their positions in the company. FMR LLC grew its holdings in Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after acquiring an additional 511,256 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Nurix Therapeutics in the third quarter worth about $7,879,000. Patient Square Capital LP purchased a new position in Nurix Therapeutics during the 3rd quarter valued at about $7,320,000. Wellington Management Group LLP raised its position in Nurix Therapeutics by 8.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock valued at $78,243,000 after purchasing an additional 280,240 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after buying an additional 235,971 shares during the period.

Nurix Therapeutics Trading Down 5.7 %

Nurix Therapeutics stock opened at $12.58 on Wednesday. The firm has a market cap of $954.66 million, a price-to-earnings ratio of -4.35 and a beta of 2.18. Nurix Therapeutics, Inc. has a 12 month low of $11.90 and a 12 month high of $29.56. The stock has a fifty day simple moving average of $16.76 and a two-hundred day simple moving average of $20.59.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NRIX. Morgan Stanley upped their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Monday, February 3rd. BTIG Research began coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 target price for the company. Leerink Partnrs upgraded shares of Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Stifel Nicolaus lifted their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, HC Wainwright upped their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 over the last quarter. Company insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.